{"disease":{"id":"ovarian-neoplasm-epithelial","name":"ovarian neoplasm epithelial"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04111978","title":"MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":540,"lead_sponsor_name":"Swiss GO Trial Group","has_results":false},{"nct_id":"NCT04794322","title":"Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT06103214","title":"The Effects of Hemodilution Methods in Patients Undergoing Primary Debulking Gynaecological Surgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":144,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT03371693","title":"Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":112,"lead_sponsor_name":"Zhongnan Hospital","has_results":false},{"nct_id":"NCT05605535","title":"Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":88,"lead_sponsor_name":"CanariaBio Inc.","has_results":false},{"nct_id":"NCT05001282","title":"A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":79,"lead_sponsor_name":"Elucida Oncology","has_results":false},{"nct_id":"NCT04566952","title":"Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":68,"lead_sponsor_name":"Xiaoxiang Chen","has_results":false},{"nct_id":"NCT04253327","title":"Distress, Anxiety and Psychosexual Health in BOT","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Universitair Ziekenhuis Brussel","has_results":false},{"nct_id":"NCT04807166","title":"Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":56,"lead_sponsor_name":"Wenjun Cheng","has_results":false},{"nct_id":"NCT04402333","title":"Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival","phase":"","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Royal Surrey County Hospital NHS Foundation Trust","has_results":false},{"nct_id":"NCT03562897","title":"Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Catalysis SL","has_results":false},{"nct_id":"NCT04556071","title":"Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":32,"lead_sponsor_name":"Xiaoxiang Chen","has_results":false},{"nct_id":"NCT06728670","title":"Pharmacokinetic Study of Tranexamic Acid","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT04780945","title":"Functional Analysis of BRCAness","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT05960630","title":"MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Royal Surrey County Hospital NHS Foundation Trust","has_results":false},{"nct_id":"NCT05261490","title":"Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Pfizer","has_results":true}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}